Michael Dyer, Ph.D., St. Jude Children's Research Hospital (IMAGE)

St. Jude Children's Research Hospital

Michael Dyer, Ph.D., St. Jude Children's Research Hospital

Caption

"Overall, survival for patients with recurrent rhabdomyosarcoma is just 17 percent, and until now nothing was known about how tumors evolve in response to therapy," said corresponding author Michael Dyer, Ph.D., a member of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute Investigator.

Credit

St. Jude Children's Research Hospital Biomedical Communications

Usage Restrictions

use credit

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.